{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:45:38Z","timestamp":1792025138052,"version":"4.4.0"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Regulatory Toxicology and Pharmacology"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.yrtph.2024.105715","type":"journal-article","created":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T21:44:23Z","timestamp":1728078263000},"page":"105715","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Safety assessment of drug impurities for patient safety: A comprehensive review"],"prefix":"10.1016","volume":"153","author":[{"given":"Frank","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.yrtph.2024.105715_bib1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0193339","article-title":"Assessment of the immunogenicity of residual host cell protein impurities of OsrHSA","volume":"13","author":"Abiri","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.yrtph.2024.105715_bib2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.yrtph.2016.02.004","article-title":"Principles and procedures for implementation of ICH M7 recommended (Q)SAR analyses","volume":"77","author":"Amberg","year":"2016","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2024.105715_bib3","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.yrtph.2018.12.007","article-title":"Principles and procedures for handling out-of-domain and indeterminate results as part of ICH M7 recommended (Q)SAR analyses","volume":"102","author":"Amberg","year":"2019","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"2","key":"10.1016\/j.yrtph.2024.105715_bib4","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1093\/toxsci\/kfm058","article-title":"Development of safety qualification thresholds and their use in orally inhaled and nasal drug product evaluation","volume":"97","author":"Ball","year":"2007","journal-title":"Toxicol. Sci."},{"issue":"1","key":"10.1016\/j.yrtph.2024.105715_bib5","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.yrtph.2015.07.018","article-title":"Establishing best practise in the application of expert review of mutagenicity under ICH M7","volume":"73","author":"Barber","year":"2015","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"6","key":"10.1016\/j.yrtph.2024.105715_bib7","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1177\/1091581809349195","article-title":"Overview of genotoxic impurities in pharmaceutical development","volume":"28","author":"Bercu","year":"2009","journal-title":"Int. J. Toxicol."},{"key":"10.1016\/j.yrtph.2024.105715_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2023.105415","article-title":"Acceptable intakes (AIs) for 11 small molecule N-nitrosamines (NAs)","volume":"142","author":"Bercu","year":"2023","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"6","key":"10.1016\/j.yrtph.2024.105715_bib9","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.xphs.2022.04.016","article-title":"A nitrite excipient database: a useful tool to support N-nitrosamine risk assessments for drug products","volume":"112","author":"Boetzel","year":"2023","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.yrtph.2024.105715_bib10","series-title":"Chemistry, Molecular Sciences and Chemical Engineering","first-page":"p233","article-title":"Computational models to predict toxicological endpoints in drug discovery and strategies for data integration","author":"Brigo","year":"2017"},{"key":"10.1016\/j.yrtph.2024.105715_bib11","doi-asserted-by":"crossref","first-page":"123","DOI":"10.5731\/pdajpst.2015.01037","article-title":"Industry perspective on the medical risk of visible particles in injectable drug products","volume":"69","author":"Bukofzer","year":"2015","journal-title":"PDA J. Pharm. Sci. Tech."},{"issue":"12","key":"10.1016\/j.yrtph.2024.105715_bib12","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1016\/j.xphs.2023.10.001","article-title":"Revisiting the landscape of potential small and drug substance related nitrosamines in pharmaceuticals","volume":"112","author":"Burns","year":"2023","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.yrtph.2024.105715_bib13","first-page":"52","article-title":"Defining your product profile and maintaining control over it, part 2","volume":"3","author":"Champion","year":"2005","journal-title":"BioProcess Int"},{"issue":"10","key":"10.1016\/j.yrtph.2024.105715_bib14","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1021\/acs.oprd.3c00153","article-title":"Formation of N-nitrosamine drug substance related impurities in medicines: a regulatory perspective on risk factors and mitigation strategies","volume":"27","author":"Cioc","year":"2023","journal-title":"Org. Process Res. Dev."},{"issue":"15","key":"10.1016\/j.yrtph.2024.105715_bib16","doi-asserted-by":"crossref","first-page":"9006","DOI":"10.1021\/acs.analchem.8b01208","article-title":"Large-scale assessment of extractables and leachables in single-use bags for biomanufacturing","volume":"90","author":"Dorival-Garc\u00eda","year":"2018","journal-title":"Anal. Chem."},{"issue":"6","key":"10.1016\/j.yrtph.2024.105715_bib17","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.3109\/07388551.2015.1084266","article-title":"Human cell lines for biopharmaceutical manufacturing: history, status, and future perspectives","volume":"36","author":"Dumont","year":"2016","journal-title":"Crit. Rev. Biotechnol."},{"issue":"3","key":"10.1016\/j.yrtph.2024.105715_bib18","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1089\/apb.2022.0020","article-title":"FDA guidance on shedding and environmental impact in clinical trials involving gene therapy products","volume":"27","author":"Eisenman","year":"2022","journal-title":"Appl. Biosaf."},{"issue":"4","key":"10.1016\/j.yrtph.2024.105715_bib19","article-title":"Safety based limits for the control of impurities in drug substances and drug products: a review","volume":"1","author":"Elder","year":"2017","journal-title":"Glob. J. Pharm. Pharm. Sci."},{"key":"10.1016\/j.yrtph.2024.105715_bib72","unstructured":"European Medicine Agency (EMA), 2010. Questions and answers on the \u201cGuideline on the limits of genotoxic impurities.\u201d EMEA\/CHMP\/SWP\/431994\/2007, Revision 3 https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/questions-and-answers-guideline-limits-genotoxic-impurities_en.pdf. (Accessed 7 April 2024)."},{"key":"10.1016\/j.yrtph.2024.105715_bib23","year":"2024"},{"key":"10.1016\/j.yrtph.2024.105715_bib24","series-title":"Procedure under Article 5(3) of Regulation EC (No) 726\/2004. EMA\/369136\/2020","article-title":"Assessment report. Nitrosamine impurities in human medicinal products","year":"2020"},{"key":"10.1016\/j.yrtph.2024.105715_bib25","article-title":"Questions and answers on \u201cInformation on nitrosamines for marketing authorisation holders.\u201d","volume":"3","year":"2020","journal-title":"EMA\/CHMP\/428592\/2019 Rev"},{"key":"10.1016\/j.yrtph.2024.105715_bib26","article-title":"Questions and answers for marketing authorisation holders\/applicants on the CHMP opinion for the Article 5(3) of Regulation (EC) No 726\/2004 referral on nitrosamine impurities in human medicinal products","volume":"16","year":"2023","journal-title":"EMA\/409815\/2020 Rev"},{"issue":"4","key":"10.1016\/j.yrtph.2024.105715_bib28","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1002\/bit.22982","article-title":"Fragmentation of a highly purified monoclonal antibody attributed to residual CHO cell protease activity","volume":"108","author":"Gao","year":"2011","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.yrtph.2024.105715_bib29","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.yrtph.2016.12.011","article-title":"Management of organic impurities in small molecule medicinal products: deriving safe limits for use in early development","volume":"84","author":"Harvey","year":"2017","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"11\u201312","key":"10.1016\/j.yrtph.2024.105715_bib30","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1089\/hum.2023.006","article-title":"Quantitation of residual host cell dna in recombinant adeno-associated virus using droplet digital polymerase chain reaction","volume":"34","author":"Higashiyama","year":"2023","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.yrtph.2024.105715_bib31","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s41021-020-00163-1","article-title":"An assessment of mutagenicity of chemical substances by (quantitative) structure\u2013activity relationship","volume":"42","author":"Honma","year":"2020","journal-title":"Genes Environ"},{"key":"10.1016\/j.yrtph.2024.105715_bib32","year":"2006"},{"key":"10.1016\/j.yrtph.2024.105715_bib33","year":"2006"},{"key":"10.1016\/j.yrtph.2024.105715_bib34","year":"2009"},{"key":"10.1016\/j.yrtph.2024.105715_bib35","year":"2009"},{"key":"10.1016\/j.yrtph.2024.105715_bib36","year":"2022"},{"key":"10.1016\/j.yrtph.2024.105715_bib37","year":"2023"},{"key":"10.1016\/j.yrtph.2024.105715_bib38","year":"2024"},{"issue":"6","key":"10.1016\/j.yrtph.2024.105715_bib39","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1208\/s12248-016-9948-4","article-title":"Evaluating immunogenicity risk due to host cell protein impurities in antibody-based biotherapeutics","volume":"18","author":"Jawa","year":"2016","journal-title":"AAPS J."},{"issue":"7","key":"10.1016\/j.yrtph.2024.105715_bib40","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.jcyt.2024.04.067","article-title":"The science and practice of current environmental risk assessment for gene therapy: a review","volume":"26","author":"Liu","year":"2024","journal-title":"Cytotherapy"},{"key":"10.1016\/j.yrtph.2024.105715_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2023.105335","article-title":"Semiquantitative sensitization safety assessment of extractable and leachables associated with parenteral pharmaceutical products","volume":"138","author":"Liu","year":"2023","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"7","key":"10.1016\/j.yrtph.2024.105715_bib71","doi-asserted-by":"crossref","first-page":"100175","DOI":"10.1016\/j.crtox.2024.100175","article-title":"Visible particles in parenteral drug products: a review of current safety assessment practice","volume":"9","author":"Liu","year":"2024","journal-title":"Curr. Res. Toxicol."},{"key":"10.1016\/j.yrtph.2024.105715_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2023.105559","article-title":"Non-mutagenic impurities \u2013 recent industry experience of using dose durational limits in drug development","volume":"147","author":"Lortie","year":"2024","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"11","key":"10.1016\/j.yrtph.2024.105715_bib44","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1016\/j.xphs.2020.07.026","article-title":"A risk-based approach to evaluate and control elemental impurities in therapeutic proteins","volume":"109","author":"Luo","year":"2020","journal-title":"J Pharm Sci"},{"issue":"4","key":"10.1016\/j.yrtph.2024.105715_bib45","doi-asserted-by":"crossref","first-page":"392","DOI":"10.5731\/pdajpst.2015.006189","article-title":"A biopharmaceutical industry perspective on the control of visible particles in biotechnology-derived injectable drug products","volume":"70","author":"Mathonet","year":"2016","journal-title":"PDA J. Pharm. Sci. Technol."},{"key":"10.1016\/j.yrtph.2024.105715_bib46","author":"Narhi"},{"key":"10.1016\/j.yrtph.2024.105715_bib47","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41587-020-0741-7","article-title":"A long-term study of AAV gene therapy in dogs with hemophilia A identifies clonal expansions of transduced liver cells","volume":"39","author":"Nguyen","year":"2021","journal-title":"Nat. Biotechnol."},{"issue":"10","key":"10.1016\/j.yrtph.2024.105715_bib48","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1021\/acs.oprd.3c00100","article-title":"The nitrosamine \u201csaga\u201d: lessons learned from five years of scrutiny","volume":"27","author":"Nudelman","year":"2023","journal-title":"Org. Process Res. Dev."},{"issue":"4","key":"10.1016\/j.yrtph.2024.105715_bib49","first-page":"8402","article-title":"Drug-excipient interactions: an overview on mechanisms and effects on drug stability and bioavailability","volume":"25","author":"Omari","year":"2021","journal-title":"Ann. Rom. Soc. Cell Biol."},{"issue":"36","key":"10.1016\/j.yrtph.2024.105715_bib50","first-page":"86","article-title":"Early development GMPs for small-molecule specifications: an industry perspective (Part V)","volume":"10","author":"O'Connor","year":"2012","journal-title":"Pharm Technol."},{"issue":"5","key":"10.1016\/j.yrtph.2024.105715_bib51","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.xphs.2023.01.017","article-title":"The Impact of n-nitrosamine impurities on clinical drug development","volume":"112","author":"Paglialunga","year":"2023","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.yrtph.2024.105715_bib52","series-title":"3rd PQRI\/FDA Conference on Advancing Product Quality","article-title":"Overview of thresholds and best practices for extractable and leachable","author":"Paskiet","year":"2017"},{"issue":"5","key":"10.1016\/j.yrtph.2024.105715_bib53","doi-asserted-by":"crossref","first-page":"430","DOI":"10.5731\/pdajpst.2013.00936","article-title":"The Product Quality Research Institute (PQRI) leachables and extractables working group initiatives for parenteral and ophthalmic drug product (PODP)","volume":"67","author":"Paskiet","year":"2013","journal-title":"PDA J. Pharm. Sci. Technol."},{"issue":"2","key":"10.1016\/j.yrtph.2024.105715_bib54","first-page":"91","article-title":"Particulate matter in injectable drugs: evaluation of risks to patients","volume":"1","author":"Perez","year":"2016","journal-title":"J. Pharm. Techno. Hosp. Pharm."},{"issue":"1","key":"10.1016\/j.yrtph.2024.105715_bib55","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1021\/acs.oprd.9b00479","article-title":"Control strategy expectations in early clinical phase synthetic oncology programs: two global regulatory case studies","volume":"24","author":"Roberts","year":"2019","journal-title":"Org. Process Res. Dev."},{"key":"10.1016\/j.yrtph.2024.105715_bib56","series-title":"Handbook of Pharmaceutical Excipients","author":"Sheskey","year":"2020"},{"issue":"5","key":"10.1016\/j.yrtph.2024.105715_bib57","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.xphs.2021.10.012","article-title":"ICH Q3D drug product elemental risk assessment: the use of an elemental impurities excipients database","volume":"111","author":"Torres","year":"2022","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.yrtph.2024.105715_bib73","series-title":"Guidance for industry. Characterization and qualification of cell substrates and other biological materials used in the production of viral vaccines for infectious disease indications","year":"2010"},{"key":"10.1016\/j.yrtph.2024.105715_bib61","article-title":"Control of nitrosamine impurities. Guidance for industry","volume":"1","year":"2021","journal-title":"Rev"},{"key":"10.1016\/j.yrtph.2024.105715_bib62","article-title":"Guidance for industry","year":"2023","journal-title":"Recommended acceptable intake limits for nitrosamine drug substance-related impurities (NDSRIs)"},{"key":"10.1016\/j.yrtph.2024.105715_bib64","year":"2013"},{"key":"10.1016\/j.yrtph.2024.105715_bib65","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/bit.23343","article-title":"Residual DNA analysis in biologics development: review of measurement and quantitation technologies and future directions","volume":"109","author":"Wang","year":"2012","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.yrtph.2024.105715_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2019.104524","article-title":"Qualification of impurities based on metabolite data","volume":"110","author":"Weidolf","year":"2020","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"4","key":"10.1016\/j.yrtph.2024.105715_bib68","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1208\/s12249-011-9677-z","article-title":"Reactive impurities in excipients: profiling, identification and mitigation of drug-excipient incompatibility","volume":"12","author":"Wu","year":"2011","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.yrtph.2024.105715_bib69","doi-asserted-by":"crossref","first-page":"155","DOI":"10.5731\/pdajpst.2013.00910","article-title":"Establishing acceptable limits of residual DNA","volume":"67","author":"Yang","year":"2013","journal-title":"PDA J. Pharm. Sci. Technol."},{"key":"10.1016\/j.yrtph.2024.105715_bib70","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.trac.2017.11.003","article-title":"Reactive impurities in large and small molecule pharmaceutical excipients \u2013 a review","volume":"101","author":"Zhang","year":"2018","journal-title":"TrAC Trends Anal. Chem."}],"container-title":["Regulatory Toxicology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230024001569?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230024001569?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T06:50:51Z","timestamp":1755067851000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0273230024001569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":61,"alternative-id":["S0273230024001569"],"URL":"https:\/\/doi.org\/10.1016\/j.yrtph.2024.105715","relation":{},"ISSN":["0273-2300"],"issn-type":[{"value":"0273-2300","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety assessment of drug impurities for patient safety: A comprehensive review","name":"articletitle","label":"Article Title"},{"value":"Regulatory Toxicology and Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yrtph.2024.105715","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105715"}}